All In Biotech

Drug Trial Radar · NCT01256658

A Community Setting Study of Malaria After Systematic Treatment of Symptomatic Carriers of P. Falciparum With COA566 (Coartem®)

A Cluster Randomized, Single-centre, Controlled, Parallel,12-month Prospective Study and Additional 12-month Follow-up in Africa of Malaria Incidence in a Community Setting Following Systematic Treatment of P. Falciparum Asymptomatic Carriers With Artemether-lumefantrine (Coartem® / Coartem® Dispersible)

Last checked: Nov 19, 2026Latest source record: Feb 10, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 14,075 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

14,075

Actual

Start

Nov 2010

Primary completion

Jul 2012

Study completion Jul 2012

Sponsor

Lead sponsor
NovartisNovartis (NVS)
Sponsor type
Industry
First posted
Dec 8, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study assessed the impact of the systematic detection by Rapid Diagnostic Test (RDT) and treatment of asymptomatic carriers of malaria parasites (P. falciparum) with COA566 on a number of clinical malaria cases in children less than 5 years of age and the improvement of hemoglobin levels in the overall population.

Conditions

  • Malaria

Interventions

  • COA566Drug

    COA566 tablets or dispersible tablets twice daily during 3 days; dosage according to body weight.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000/μL (SMRC5000s) Per Person-year in Infants and Children (<5 Years) in Post Community Screening Campaign (CSC) at Month 12 (Per Cluster)Time frame: Month 12 of period 1
  2. Change in Hemoglobin Level (g/dL) in Asymptomatic Carriers >6 Months of Age (Per Cluster)Time frame: Day 1 and day 28 of period 1

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Burkina Faso, Burkina Faso

  • Centre National de Recherche et de Formation sur le Paludisme

    Ouagadougou, Ouagadougou, Burkina Faso

  • Novartis Investigative site

    Ouagadougou, Ouagadougou, Burkina Faso

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.